(Rac)-Benpyrine, the racemic mixture of Benpyrine, is a potent and orally bioactive TNF-α inhibitor with the potential for research into TNF-α mediated inflammatory and autoimmune diseases.
Physicochemical Properties
Molecular Formula | C16H16N6O |
Molecular Weight | 308.33784198761 |
Exact Mass | 308.14 |
Elemental Analysis | C, 62.32; H, 5.23; N, 27.26; O, 5.19 |
CAS # | 1333714-43-4 |
Related CAS # | Benpyrine;2550398-89-3;(R)-Benpyrine |
PubChem CID | 53605452 |
Appearance | White to off-white solid powder |
LogP | 1.2 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 4 |
Heavy Atom Count | 23 |
Complexity | 427 |
Defined Atom Stereocenter Count | 0 |
InChi Key | HUWOMAVUXTXEKT-UHFFFAOYSA-N |
InChi Code | InChI=1S/C16H16N6O/c23-13-6-12(8-22(13)7-11-4-2-1-3-5-11)21-16-14-15(18-9-17-14)19-10-20-16/h1-5,9-10,12H,6-8H2,(H2,17,18,19,20,21) |
Chemical Name | 1-benzyl-4-(7H-purin-6-ylamino)pyrrolidin-2-one |
Synonyms | (Rac)-Benpyrine; Benpyrine racemate |
HS Tariff Code | 2934.99.9001 |
Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
Targets | TNF-α |
ln Vitro | (Rac)-Benpyrine (Compound 001; 5-10 μM; 24 hours) treatment inhibits the level of nuclear expression of the TNF-α downstream pathway protein NF-κB in RAW264.7 macrophages[1]. |
ln Vivo | (Rac)-Benpyrine (Compound 001; 25-50 mg/kg; oral gavage; daily; for 3 weeks; Kunming mice) treatment clearly lowers inflammatory cytokines IFN-γ, IL-1β and IL-6 in blood serum, and clearly increases the anti-inflammatory factor IL-10. It also clearly slows the progression of foot swelling associated with arthritis, but does not reduce the weight index increase caused by arthritis[1]. |
Cell Assay | In a glass chamber, RAW 264.7 cells were expanded to 50–70% confluence, pretreated for 12 hours with DMSO or benpyrine, and then stimulated for 2 hours with 10 ng/mL TNF-. After PBS washing to end the cell treatments, the cells were fixed in freshly made 4% paraformaldehyde in PBS for 20 minutes. After three PBS washes, the fixed cells were permeabilized with 0.25% Triton X-100 in PBS for 10 minutes. We added the NF-B/p65 antibody at a 1:1000 dilution and incubated it at 4 °C overnight after blocking with 2 mg/mL BSA for 1 h at room temperature. We then washed the area three times with PBS and incubated it in the dark for 1 h at room temperature with a 1:500 dilution of the secondary antibody. Finally, 4′,6-diamidino-2-phenyl indole (DAPI) was used to stain the nuclei at 37 °C for 30 min in the dark. |
References |
[1]. Compound with TNF- α inhibitory activity and application. CN111320630A. |
Solubility Data
Solubility (In Vitro) | DMSO: 10~31 mg/mL (32.4~100.5 mM) |
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (4.05 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (4.05 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 1.25 mg/mL (4.05 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.2432 mL | 16.2159 mL | 32.4317 mL | |
5 mM | 0.6486 mL | 3.2432 mL | 6.4863 mL | |
10 mM | 0.3243 mL | 1.6216 mL | 3.2432 mL |